Native GLP-1 has a half-life of minutes — far too short to be a practical medicine.
Modern GLP-1 drugs attach a fatty-acid chain that binds albumin, an abundant, long-circulating blood protein.
Bound to albumin, the molecule resists rapid breakdown, stretching the half-life to about a week.
Once the half-life is ~5–7 days, a weekly dose keeps levels in a workable range — cadence follows half-life.
Semaglutide (~7 days) and tirzepatide (~5 days) are both engineered this way.
Weekly dosing is not arbitrary — it is a direct consequence of engineering these compounds to survive in the body for days rather than minutes.
In plain terms: the schedule matches how long the drug lasts, and these drugs were rebuilt to last about a week.
Fig. Tirzepatide is a single 39-residue peptide that activates two incretin receptors — GIP and GLP-1 — via one molecule (a dual agonist). Receptor-pharmacology analyses describe it as imbalanced, engaging the GIP receptor more than GLP-1. Semaglutide, by contrast, activates GLP-1 alone.
The native problem
The natural incretin hormone GLP-1 — a gut hormone released after eating that helps regulate blood sugar and appetite — has a half-life measured in minutes4. It is broken down almost immediately by an enzyme called DPP-4 and cleared by the kidneys. A drug that behaved that way would need near-constant administration. So the compounds are modified to resist that breakdown.
How the half-life is extended
Modern GLP-1 agonists use a structural trick: a fatty-acid chain that binds to albumin, the most abundant and long-circulating protein in blood. Bound to albumin, the compound is shielded from rapid clearance, stretching its half-life from minutes to about a week1. Semaglutide was specifically designed this way, and its ~1-week half-life was later confirmed in patients2. (The same albumin-binding principle appears in CJC-1295's DAC form.)
In plain terms: attaching a "grappling hook" to a long-lasting blood protein lets the drug ride along instead of being flushed out.
From half-life to schedule
Once the half-life is ~5–7 days, the dosing cadence follows: a compound still ~50% present a week later can be given weekly and maintain a workable level curve, accumulating toward steady-state over the first several weeks.
This is educational pharmacology, not dosing guidance. Actual schedules belong to the product label and a clinician.
Frequently asked
Why can semaglutide be taken only once a week?
Native GLP-1 has a half-life of minutes. Modern GLP-1 medications are engineered — through modifications like a fatty-acid chain that binds albumin — to resist rapid breakdown, extending the half-life to about a week and enabling once-weekly dosing.
What is albumin binding?
Albumin is the most abundant protein in blood and circulates for weeks. GLP-1 drugs carry a fatty-acid chain that latches onto albumin, so the drug rides along, shielded from the enzymes and kidneys that would otherwise clear it quickly.
Are all GLP-1 medications weekly?
No. The long-acting injectables like semaglutide and tirzepatide are weekly because their half-life is days. Some earlier or oral GLP-1 products are dosed daily because they clear faster.
References
Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.J Med Chem. 2015. DOI 10.1021/acs.jmedchem.5b01016
Overgaard RV, Delff PH, Petri KCC, et al. Population Pharmacokinetics of Semaglutide for Type 2 Diabetes.Diabetes Ther. 2019. DOI 10.1007/s13300-019-0581-y
Furihata K, Mimura H, Urva S, et al. A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.Diabetes Obes Metab. 2022. DOI 10.1111/dom.14572
Zyra Labs is a research and educational utility. Nothing on this page is medical advice, a dosing recommendation, or an endorsement of any compound. We never sell or source compounds and refuse sourcing questions. Consult a qualified clinician for decisions about your health.